Search - tctmd.com

Displaying 281 - 300 of 414

Sort: Relevancy | Date

News Conference News TCT 2012

TRILOGY ACS Substudy: Angiography Prior to Prasugrel Therapy Reduces CV Events

October 25, 2012

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

Presentation TCT 2012

Prasugrel Update: TRILOGY

Presenter: E. Magnus Ohman

October 24, 2012

Presentation TCT 2012

Prasugrel Is the Gold Standard!

Presenter: Matthew Price

October 24, 2012

News Conference News TCT 2012

Wednesday, TCT 2012 Dailies

October 24, 2012

Presentation TCT 2012

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

Presenter: Stephen Wiviott

October 24, 2012

News Conference News TCT 2012

Tailored Clopidogrel Therapy Bests Prasugrel at Control of Platelet Reactivity in ACS

October 24, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Conference News TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

October 24, 2012

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Presentation TCT 2012

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

Presenter: Renato Valenti

October 23, 2012

Presentation TCT 2012

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Presenter: Joseph Jakubowski

October 23, 2012

Presentation TCT 2012

Pro: Prasugrel!

Presenter: Giuseppe Biondi Zoccai

October 23, 2012

News Conference News TCT 2012

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

October 23, 2012

News Industry News

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

October 23, 2012

Presentation TCT 2012

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

Presenter: Paul Gurbel

October 22, 2012

Presentation TCT 2012

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Presenter: Laurent Bonello

October 22, 2012

News Daily News

Un Informe del Registro CathPCI Detalla los Patrones Contemporáneos de Práctica Clínica en EE.UU.

Caitlin E. Cox

October 18, 2012

News Daily News

Un Estudio Avala ½ Dosis de Prasugrel en Pacientes de Poco Peso con EAC

October 18, 2012

News Daily News

Study Supports Half-Dose Prasugrel for Low-Weight CAD Patients

October 18, 2012

Advertisement

TRILOGY ACS Substudy: Angiography Prior to Prasugrel Therapy Reduces CV Events

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

Prasugrel Update: TRILOGY

Prasugrel Is the Gold Standard!

Wednesday, TCT 2012 Dailies

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

Tailored Clopidogrel Therapy Bests Prasugrel at Control of Platelet Reactivity in ACS

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

Presentations Examine Multiple Facets of Antiplatelet Agents

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

TCT-51. Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-eluting Stents: Insight from the Florence Left Main-PCI...

TCT-49. A Comparison of 5 mg Prasugrel with 75 mg Clopidogrel in Very Elderly Coronary Artery Disease Patients: Pharmacodynamics and Rates of High on-Treatment Reactivity

Pro: Prasugrel!

PARADOX: Smoking Enhances Effect of Clopidogrel, Prasugrel Unaffected by Smoking Status

New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient® (Prasugrel) or Plavix® (Clopidogrel) Pre

PARADOX: A Prospective, Randomized Trial of Clopidogrel and Prasugrel in Smokers and Non-Smokers

A Prospective, Randomized Trial of Tailored Clopidogrel Therapy vs. Prasugrel in Patients with High On-Treatment Platelet Reactivity

Un Informe del Registro CathPCI Detalla los Patrones Contemporáneos de Práctica Clínica en EE.UU.

Un Estudio Avala ½ Dosis de Prasugrel en Pacientes de Poco Peso con EAC

Study Supports Half-Dose Prasugrel for Low-Weight CAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content